Sanofi, Regeneron launch late-stage cancer studies

Sanofi-Aventis and Regeneron say that they have launched two Phase III trials for aflibercept--or VEGF Trap--with chemotherapy for lung and prostate cancer. The program has enormous potential if it succeeds in Phase III. The injectable therapy is designed to block the formation of abnormal blood vessels. VEGF triggers these new blood vessels to form in a process called angiogenesis. The blockbuster Avastin is currently the leading therapy in this field. Sanofi will provide an update on the program during its R&D day on September 17. The companies believe they can start seeking approval of the drug as early as next year.

- check out the release

Related Articles:
Regeneron, Genentech go head-to-head. Report
Regeneron wins rich pact for VEGF trap. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.